Business context and reporting period
Entity discrepancy: The request identifies Gridai Technologies Corp., but the supplied Form 10-K is for AzurRx BioPharma, Inc. This summary reflects the filing text and should not be attributed to Gridai without verification. The filing covers the fiscal year ended December 31, 2016; it is an annual report, not a standalone fourth-quarter report.
AzurRx was a development-stage biopharmaceutical company developing non-systemic biologics for gastrointestinal disorders. Its lead candidate, MS1819, entered a Phase II trial for exocrine pancreatic insufficiency associated with chronic pancreatitis; AZX1101 remained preclinical. The company reported no product revenue.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | None | None |
| R&D expense | $2.50 million | $1.40 million |
| G&A expense | $4.13 million | $3.33 million |
| Operating loss | $6.33 million | $4.73 million |
| Net loss | $14.59 million | $5.93 million |
| Net loss per share | $2.24 | $1.63 |
| Cash used in operating activities | $4.53 million | $4.17 million |
Margins are not meaningful because the company had no revenue. At year-end, cash was $1.77 million, working capital was approximately $623,000, total assets were $6.75 million, and total liabilities were $3.54 million. Current liabilities were $2.34 million, including $155,000 of notes payable; convertible debt and its associated warrant liability had been eliminated through the IPO conversion. Contingent consideration was $1.20 million. The filing states cash was expected to fund operations only through July 2017 and that substantial doubt existed about the company’s ability to continue as a going concern through March 2018.
Material changes versus 2015
- Net loss increased by $8.66 million. Higher interest expense ($5.94 million versus $1.59 million) and a $2.33 million unfavorable warrant fair-value adjustment were major contributors, alongside higher operating expenses.
- R&D expense rose $1.10 million, primarily for additional MS1819 manufacturing batches; G&A increased $798,000, including public-company costs and noncash restricted-stock expense.
- The October 2016 IPO sold 960,000 shares at $5.50 each, generating $5.28 million gross and approximately $3.51 million net proceeds. Convertible debt converted into 2,642,160 common shares; the filing also records $2.74 million of interest expense for warrants issued in exchange for investor lockups.
- Year-end cash increased from $582,000 to $1.77 million, while current liabilities fell from $8.82 million to $2.34 million, principally following conversion of debt at the IPO.
Outlook, risks and unusual items
- Management expected to continue enrolling approximately 15 patients in the Australia/New Zealand MS1819 Phase II dose-escalation study and, subject to results and regulatory interactions, expected to submit a U.S. IND by the fourth quarter of 2017. These are historical expectations stated in the 2016 filing, not current guidance.
- AZX1101 plans included initial animal and toxicology work in 2017; management said IPO proceeds would not fund the program beyond these initial steps, so further financing would be needed.
- Key risks include the need for additional capital, clinical and regulatory failure or delay, patient enrollment, reliance on third-party manufacturers and research organizations, competition, and dependence on licensed intellectual property. The MS1819 Phase I/IIa study was small and was not designed to establish statistical efficacy; the filing reported no serious adverse events but a non-statistically significant primary-endpoint difference.
- The auditor issued an unmodified opinion on the financial statements but highlighted substantial doubt about going concern. Management also identified a material weakness in internal control over financial reporting; the auditor did not opine on internal-control effectiveness.
- No material pending legal proceedings were reported. The company disclosed related-party payables and consulting arrangements, including amounts due to entities or individuals connected with senior management and directors.
Important facts for investors to verify
- Confirm the issuer and filing match the intended company: the supplied filing names AzurRx BioPharma, Inc., not Gridai Technologies Corp.
- Verify subsequent financing, cash runway, liquidity, and the resolution of the disclosed going-concern uncertainty.
- Check actual MS1819 trial progress and results, regulatory submissions, and whether the stated 2017 milestones occurred.
- Review the material-weakness remediation status and subsequent auditor or control disclosures.
- Assess potential dilution and obligations from warrants, equity awards, licensing terms, contingent payments, and related-party balances.